On the theory of resonances in non-relativistic QED and related models

We study the mathematical theory of quantum resonances in the standard model of non-relativistic QED and in Nelson's model. In particular, we estimate the survival probability of metastable states corresponding to quantum resonances and relate the resonances to poles of an analytic continuation of matrix elements of the resolvent of the quantum Hamiltonian.Comment: 28 page

On the Dynamics of solitons in the nonlinear Schroedinger equation

We study the behavior of the soliton solutions of the equation i((\partial{\psi})/(\partialt))=-(1/(2m)){\Delta}{\psi}+(1/2)W_{{\epsilon}}'({\psi})+V(x){\psi} where W_{{\epsilon}}' is a suitable nonlinear term which is singular for {\epsilon}=0. We use the "strong" nonlinearity to obtain results on existence, shape, stability and dynamics of the soliton. The main result of this paper (Theorem 1) shows that for {\epsilon}\to0 the orbit of our soliton approaches the orbit of a classical particle in a potential V(x).Comment: 29 page

Vardenafil Oral Dispersible Films (ODFs) with advanced dissolution, palatability, and bioavailability

Oral, quick response, and on demand, also known as a spontaneous oral treatment for erectile dysfunction, is highly needed by both patients and physicians. Vardenafil is selective (fewer side effects) and more effective in difficult-to-treat conditions than sildenafil. This study aims at fostering the dual objectives of using biomolecules such as artificial sweetening agents to solubilize and mask the bitterness of vardenafil loaded on biodegradable polymeric materials (PVA, MC, SA, and PVP K30) to fabricate oral, fast-dissolving films (vardenafil ODFs) in the mouth without the need for water to ingest the dosage form. Furthermore, coprecipitated-dispersed mixtures of vardenafil and three sweeteners (sorbitol, acesulfame K, and sucralose) were prepared and characterized using FTIR, DSC, and solubility studies. Moreover, eight different vardenafil ODFs were prepared using the solvent-casting method. Modified gustatory sensation test, in vitro disintegration, and release studies were performed. In addition, the optimized ODF (F8) was compared with the commercial film-coated tablets pharmacokinetically (relative bioavailability, onset, and duration of actions were estimated). The results indicated that the three sweetening agents had comparable solubilizing capacity. However, both sucralose- and acesulfame K-based ODFs have a more enhanced sweet and palatable taste than sorbitol-sweetened ODF. The SA- and PVP K30-based ODFs showed significantly faster disintegration times and release rates than MC. In conclusion, PVA has good film-forming properties, but a higher ratio of PVA adversely affected the disintegration and release characteristics. The % relative bioavailability for ODF was 126.5%, with a superior absorption rate constant (Ka) of 1.2-fold. The C(max) and estimated T(max) were compared to conventional film-coated tablets

General Adiabatic Evolution with a Gap Condition

We consider the adiabatic regime of two parameters evolution semigroups generated by linear operators that are analytic in time and satisfy the following gap condition for all times: the spectrum of the generator consists in finitely many isolated eigenvalues of finite algebraic multiplicity, away from the rest of the spectrum. The restriction of the generator to the spectral subspace corresponding to the distinguished eigenvalues is not assumed to be diagonalizable. The presence of eigenilpotents in the spectral decomposition of the generator forbids the evolution to follow the instantaneous eigenprojectors of the generator in the adiabatic limit. Making use of superadiabatic renormalization, we construct a different set of time-dependent projectors, close to the instantaneous eigeprojectors of the generator in the adiabatic limit, and an approximation of the evolution semigroup which intertwines exactly between the values of these projectors at the initial and final times. Hence, the evolution semigroup follows the constructed set of projectors in the adiabatic regime, modulo error terms we control

Resonances in Models of Spin Dependent Point Interactions

In dimension $d=1,2,3$ we define a family of two-channel Hamiltonians obtained as point perturbations of the generator of the free decoupled dynamics. Within the family we choose two Hamiltonians, $\hat H_0$ and \hat H_\ve, giving rise respectively to the unperturbed and to the perturbed evolution. The Hamiltonian $\hat H_0$ does not couple the channels and has an eigenvalue embedded in the continuous spectrum. The Hamiltonian \hat H_\ve is a small perturbation, in resolvent sense, of $\hat H_0$ and exhibits a small coupling between the channels. We take advantage of the complete solvability of our model to prove with simple arguments that the embedded eigenvalue of $\hat H_0$ shifts into a resonance for \hat H_\ve. In dimension three we analyze details of the time behavior of the projection onto the region of the spectrum close to the resonance.Comment: Changes in the proof of theorem 3, few misprints corrected, 21 page

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Effects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study

Background Early death after cancer surgery is higher in low-income and middle-income countries (LMICs) compared with in high-income countries, yet the impact of facility characteristics on early postoperative outcomes is unknown. The aim of this study was to examine the association between hospital infrastructure, resource availability, and processes on early outcomes after cancer surgery worldwide.Methods A multimethods analysis was performed as part of the GlobalSurg 3 study-a multicentre, international, prospective cohort study of patients who had surgery for breast, colorectal, or gastric cancer. The primary outcomes were 30-day mortality and 30-day major complication rates. Potentially beneficial hospital facilities were identified by variable selection to select those associated with 30-day mortality. Adjusted outcomes were determined using generalised estimating equations to account for patient characteristics and country-income group, with population stratification by hospital.Findings Between April 1, 2018, and April 23, 2019, facility-level data were collected for 9685 patients across 238 hospitals in 66 countries (91 hospitals in 20 high-income countries; 57 hospitals in 19 upper-middle-income countries; and 90 hospitals in 27 low-income to lower-middle-income countries). The availability of five hospital facilities was inversely associated with mortality: ultrasound, CT scanner, critical care unit, opioid analgesia, and oncologist. After adjustment for case-mix and country income group, hospitals with three or fewer of these facilities (62 hospitals, 1294 patients) had higher mortality compared with those with four or five (adjusted odds ratio [OR] 3.85 [95% CI 2.58-5.75]; p<0.0001), with excess mortality predominantly explained by a limited capacity to rescue following the development of major complications (63.0% vs 82.7%; OR 0.35 [0.23-0.53]; p<0.0001). Across LMICs, improvements in hospital facilities would prevent one to three deaths for every 100 patients undergoing surgery for cancer.Interpretation Hospitals with higher levels of infrastructure and resources have better outcomes after cancer surgery, independent of country income. Without urgent strengthening of hospital infrastructure and resources, the reductions in cancer-associated mortality associated with improved access will not be realised